NEOG:NGS-Neogen Corporation (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 12.14

Change

+0.18 (+1.51)%

Market Cap

USD 2.34B

Volume

2.03M

Analyst Target

USD 73.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neogen Corp, through its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+6.81 (+1.43%)

USD 41.47B
ICLR ICON PLC

-0.60 (-0.19%)

USD 25.49B
ILMN Illumina Inc

-6.16 (-5.18%)

USD 19.47B
MEDP Medpace Holdings Inc

+1.36 (+0.34%)

USD 12.27B
NTRA Natera Inc

-0.06 (-0.06%)

USD 11.20B
EXAS EXACT Sciences Corporation

-1.94 (-3.06%)

USD 10.68B
RDNT RadNet Inc

+0.47 (+0.90%)

USD 3.57B
SHC Sotera Health Co

+0.18 (+1.59%)

USD 3.10B
OLK Olink Holding AB ADR

+0.07 (+0.30%)

USD 2.72B
GH Guardant Health Inc

-0.28 (-1.47%)

USD 1.96B

ETFs Containing NEOG

KATZ:XETRA 4.65 % 0.00 %

N/A

N/A
PETZ:SW 4.65 % 0.00 %

N/A

N/A
PETZ:LSE 4.62 % 0.00 %

N/A

N/A
SBB ProShares Short SmallCap6.. 0.00 % 0.95 %

-0.05 (0%)

USD 6.49M
SDD ProShares UltraShort Smal.. 0.00 % 0.95 %

-0.09 (0%)

USD 2.52M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.63% 23% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.63% 23% F 13% F
Trailing 12 Months  
Capital Gain -29.50% 53% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.50% 53% F 28% F
Trailing 5 Years  
Capital Gain -79.50% 31% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.50% 31% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -19.64% 32% F 19% F
Dividend Return -19.64% 32% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.80% 75% C 51% F
Risk Adjusted Return -54.86% 25% F 19% F
Market Capitalization 2.34B 87% B+ 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 63.20 10% 8%
Price/Book Ratio 1.06 63% 68%
Price / Cash Flow Ratio 80.03 2% 3%
Price/Free Cash Flow Ratio 21.14 10% 12%
Management Effectiveness  
Return on Equity 0.38% 89% 59%
Return on Invested Capital 1.50% 90% 63%
Return on Assets 1.19% 89% 70%
Debt to Equity Ratio 28.25% 53% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector